Table 1 Characteristics of included studies
NO. | Author | Magnesium sulfate group | Control group | Jada scores | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | Age (years) | Female (n) | Weight (kg) | Duration of surgery (min) | Methods | Number | Age (years) | Female (n) | Weight (kg) | Duration of surgery (min) | Methods | |||
1 | Devi 2018 | 18 | 33.44±10.87 | 5 | 67.67±14.11 | - | intraarticular 20ml, 0.25% bupivacaine with 10 mg/kg of magnesium sulfate for knee arthroscopy | 18 | 37.22±13.36 | 8 | 67.39±8.33 | - | 20 ml of 0.25% bupivacaine | 3 |
2 | Kızılcık 2017 | 32 | 43.06±13.19 | 10 | - | - | 50 mg (5 ml) of levobupivacain and an additional 1.5 g magnesium sulfate (10 ml) intraarticularly for arthroscopic meniscectomy | 32 | 40.06 ± 9.24 | 8 | 7- | - | 100 mg (10 ml) of levobupivacaine intraarticularly | 4 |
3 | Lee 2012 | 28 | 60±8 | 10 | 67±11 | 90±22 | interscalene nerve block was performed with 0.5% bupivacaine 20 mL with epinephrine (1:200,000) plus either 10% magnesium sulphate 2 mL for arthroscopic rotator cuff repair | 30 | 56±8 | 13 | 71±19 | 98±45 | interscalene nerve block was performed with 0.5% bupivacaine 20 mL with epi- nephrine (1:200,000) plus normal saline 2 mL | 5 |
4 | Farouk 2009 | 20 | 36± 6 | 2 | 74±7 | 40±8 | 20 ml 0.25% bupivacaine and magnesium 150 mg for arthroscopic knee surgery | 20 | 35 ± 7 | 4 | 72 ± 8 | 41 ± 8 | 20 ml 0.25% bupivacaine | 4 |
5 | Dayioğlu 2009 | 30 | 41.2 ± 15.3 | 11 | 74.2 ± 12.1 | 56.3±20.8 | 50 mg magnesium sulfate (3 ml) following 6 mg bupivacaine 0.5% plus 10 μ g fentanyl intrathecally for knee arthroscopy | 30 | 38.7 ± 14.4 | 12 | 75.5 ± 8.1 | 52.9 ± 18.2 | 3 ml of preservative-free 0.9% NaCl following 6 mg bupivacaine 0.5% plus 10 μ g fentanyl intrathecally | 4 |
6 | Elsharnouby 2008 | 27 | 40±11 | 1 | 82±12 | - | bupivacaine 0.25% and 1 g of magnesium sulfate in 20 mL for arthroscopic knee surgery | 27 | 45±9 | 2 | 79±11 | - | 0.25% (20 mL) bupivacaine | 4 |